M Fernanda Amary1,2, Fitim Berisha1, Rafael Mozela1,3, Rebecca Gibbons1, Alice Guttridge2, Paul O'Donnell4, Daniel Baumhoer5, Roberto Tirabosco1, Adrienne M Flanagan1,2. 1. Department of Histopathology, Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK. 2. UCL Cancer Institute, Huntley Street, London, UK. 3. Department of Anatomical Pathology, A. C. Camargo Cancer Centre, Sao Paulo, Brazil. 4. Department of Radiology, Royal National Orthopaedic Hospital NHS Trust, Stanmore, UK. 5. Bone Tumour Reference Centre at the Institute of Pathology, University Hospital Basel, Basel, Switzerland.
Abstract
AIMS: We recently reported that 95% of chondroblastomas harbour a p.K36M mutation in either H3F3A (chromosome 1) or H3F3B (chromosome 17), with the majority involving H3F3B. The aim of this study was to assess the expression of the K36M-mutated protein by immunohistochemistry in a large group of tumours. METHODS AND RESULTS: One thousand eight hundred and ninety-four tumours, including 85 chondroblastomas and 10 clear-cell chondrosarcomas, were studied; of these, 82 chondroblastomas and one clear-cell chondrosarcoma known to harbour the H3F3 p.K36M mutation expressed the mutated protein. Three chondroblastomas and nine clear-cell chondrosarcomas wild type for H3F3A/H3F3B were negative for p.K36M immunoexpression. The remaining 1799 cases tested, 545 of which were known to be wild type for the H3F3A and H3F3B p.K36M mutations, included 1047 primary bone tumours, and 507 soft tissue and joint tumours. Two hundred and forty-five other tumour types not expected to harbour the mutation were negative for p.K36M immunoexpression. CONCLUSIONS: Our data demonstrate the specificity and sensitivity of this immunomarker, and will be a useful adjunct for reaching a diagnosis of chondroblastoma.
AIMS: We recently reported that 95% of chondroblastomas harbour a p.K36M mutation in either H3F3A (chromosome 1) or H3F3B (chromosome 17), with the majority involving H3F3B. The aim of this study was to assess the expression of the K36M-mutated protein by immunohistochemistry in a large group of tumours. METHODS AND RESULTS: One thousand eight hundred and ninety-four tumours, including 85 chondroblastomas and 10 clear-cell chondrosarcomas, were studied; of these, 82 chondroblastomas and one clear-cell chondrosarcoma known to harbour the H3F3 p.K36M mutation expressed the mutated protein. Three chondroblastomas and nine clear-cell chondrosarcomas wild type for H3F3A/H3F3B were negative for p.K36M immunoexpression. The remaining 1799 cases tested, 545 of which were known to be wild type for the H3F3A and H3F3Bp.K36M mutations, included 1047 primary bone tumours, and 507 soft tissue and joint tumours. Two hundred and forty-five other tumour types not expected to harbour the mutation were negative for p.K36M immunoexpression. CONCLUSIONS: Our data demonstrate the specificity and sensitivity of this immunomarker, and will be a useful adjunct for reaching a diagnosis of chondroblastoma.
Authors: Kivilcim Eren Erdogan; Marina Pacheco; Marco Gambarotti; Giovanna Magagnoli; Marta Sbaraglia; Tommaso Frisoni; Alberto Righi; Angelo Paolo Dei Tos Journal: Virchows Arch Date: 2021-01-28 Impact factor: 4.064
Authors: Inga-Marie Schaefer; Jonathan A Fletcher; G Petur Nielsen; Angela R Shih; Marco L Ferrone; Jason L Hornick; Xiaohua Qian Journal: Cancer Cytopathol Date: 2018-05-14 Impact factor: 5.284
Authors: Yajuan J Liu; Wenjing Wang; Jeffrey Yeh; Yu Wu; Jose G Mantilla; Christopher D M Fletcher; Robert W Ricciotti; Eleanor Y Chen Journal: Mod Pathol Date: 2021-03-16 Impact factor: 7.842